Zealand Pharma ASZLDPF 62 PS Ratio is 2.20 as of Jul. 01, 2026, which is 95% below its 10-year median of 48.29. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,914.49 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 934 Biotechnology companies, Zealand Pharma AS ranks better than 83.3% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zealand Pharma AS's share price is $43.77.
Zealand Pharma AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $19.93. Hence, Zealand Pharma AS's PS Ratio for today is 2.20.
The historical rank and industry rank for Zealand Pharma AS's PS Ratio or its related term are showing as below:
ZLDPF'
s PS Ratio Range Over the Past 10 Years
Min: 1.83 Med: 48.29 Max: 795.2
Current: 2.25
During the past 13 years, Zealand Pharma AS's highest PS Ratio was 795.20. The lowest was 1.83. And the median was 48.29.
ZLDPF's PS Ratio is ranked better than 83.3% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs ZLDPF: 2.25
During the past 12 months, the average Revenue per Share Growth Rate of Zealand Pharma AS was 15116.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 285.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 50.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.70% per year.
During the past 13 years, Zealand Pharma AS's highest 3-Year average Revenue per Share Growth Rate was 285.30% per year. The lowest was -60.70% per year. And the median was 4.40% per year.
Back to Basics: PS Ratio
Zealand Pharma AS (OTCPK:ZLDPF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Zealand Pharma AS PS Ratio Related Terms
Zealand Pharma AS PS Ratio Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zealand Pharma AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Zealand Pharma AS's Share Price of today is $43.77. Zealand Pharma AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.93.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Zealand Pharma AS (ZLDPF) has a PS Ratio of 2.20 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zealand Pharma AS and its competitors. This is 95% below median its historical median of 48.29. Over the past decade, Zealand Pharma AS's PS Ratio has ranged from 1.83 to 795.20. According to the industry distribution chart, Zealand Pharma AS ranks #156 out of 934 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Zealand Pharma AS's PS Ratio too high?
Zealand Pharma AS's current PS Ratio of 2.20 is 95% below median its 10-year median of 48.29. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 795.20. The Biotechnology industry median PS Ratio is 9.52. Zealand Pharma AS's value of 2.20 is 76.9% below this industry median. Based on the distribution chart, Zealand Pharma AS ranks #156 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #156 out of 934 companies for PS Ratio. This places Zealand Pharma AS in the top 17% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.52. Zealand Pharma AS's value of 2.20 is 76.9% below this benchmark. Historically, Zealand Pharma AS's own PS Ratio has ranged from 1.83 to 795.20 over the past decade. While the company's 10-year median is 48.29 vs. the industry median of 9.52, Zealand Pharma AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current PS Ratio of 2.20 is 76.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current PS Ratio is 2.20, which is 95% below median its own 10-year median of 48.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,914.49, compared to a current price of $43.77 — trading 97.7% below its estimated fair value. The current PS Ratio is 2.20, which is 95% below median its 10-year median of 48.29 and 76.9% below the Biotechnology industry median of 9.52. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current PS Ratio is 2.20 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $43.77 is trading 97.7% below its estimated GF Value™ of $1,914.49.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
PS Ratio: 2.20 (95% below median its 10-year median of 48.29)
GF Value™: $1,914.49 vs. price of $43.77 (97.7% below fair value)
Industry Position: 76.9% below the Biotechnology median (#156 of 934)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
